WO2020162485A1 - Agent antivirus et procédé destiné à l'élimination de virus - Google Patents

Agent antivirus et procédé destiné à l'élimination de virus Download PDF

Info

Publication number
WO2020162485A1
WO2020162485A1 PCT/JP2020/004291 JP2020004291W WO2020162485A1 WO 2020162485 A1 WO2020162485 A1 WO 2020162485A1 JP 2020004291 W JP2020004291 W JP 2020004291W WO 2020162485 A1 WO2020162485 A1 WO 2020162485A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
platinum
virus
silver
antiviral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/004291
Other languages
English (en)
Japanese (ja)
Inventor
正信 大北
聡史 南
甲 貴傳名
楠 呉
草刈　剛
達夫 錫谷
恭子 西山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Gas Chemicals Co Ltd
Fukushima Medical University PUC
Original Assignee
Osaka Gas Chemicals Co Ltd
Fukushima Medical University PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Gas Chemicals Co Ltd, Fukushima Medical University PUC filed Critical Osaka Gas Chemicals Co Ltd
Priority to CN202080012642.7A priority Critical patent/CN113395901A/zh
Priority to JP2020542332A priority patent/JP6820579B2/ja
Publication of WO2020162485A1 publication Critical patent/WO2020162485A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof

Definitions

  • the present invention relates to an antiviral agent and a method for removing a virus.
  • Patent Document 1 discloses a technique of incorporating nanosized platinum particles into a wet tissue to impart an antiviral effect to the wet tissue.
  • the present invention has been made in view of the above, and an object of the present invention is to provide an antiviral agent and a method for inactivating viruses, which can rapidly inactivate various viruses.
  • the present inventors have found that the above object can be achieved by employing platinum particles as an active ingredient, and have completed the present invention.
  • Item 1 An antiviral agent containing metal particles, An antiviral agent, wherein the metal particles contain platinum particles.
  • Item 2 Item 2.
  • the antiviral agent according to Item 1, wherein the metal particles further contain silver particles.
  • Item 3 Item 3.
  • Item 4 Item 4.
  • Item 5 Item 5.
  • the antiviral agent according to Item 4 wherein the total amount of the metal particles is 0.01 to 1000 mass ppm with respect to the total mass of the aqueous solvent.
  • Item 6 Item 6.
  • Item 7 Item 6.
  • Item 8 Item 8.
  • Item 8-1 Item 10. Use of the antiviral agent according to any one of items 1 to 7 for a medical device.
  • Item 9 Item 9.
  • Item 9-1 Item 9. Use of the antiviral agent according to any one of items 1 to 8 for an ophthalmic medical device.
  • Item 10 Item 10. A method for inactivating a virus, which uses the antiviral agent according to any one of Items 1 to 9.
  • various viruses can be rapidly inactivated. Moreover, according to the virus inactivation method of the present invention, various viruses can be rapidly inactivated.
  • the antiviral agent of the present invention contains metal particles. Particularly in the antiviral agent of the present invention, the metal particles contain at least platinum particles. Metal particles including platinum particles are active ingredients in antiviral agents. Below, the antiviral agent containing the said metal particle is only described as an "antiviral agent.”
  • the "antiviral action” includes, for example, the action of inactivating a virus. More specifically, the “antiviral effect” includes an effect of suppressing the growth of the virus, an effect of killing the virus, and an effect of reducing the infectivity of the virus.
  • the platinum particles have platinum (Pt) as a constituent component.
  • the platinum particles are usually formed of a simple element of platinum, but may contain a platinum compound such as platinum oxide. In addition, the platinum particles may contain an alloy of platinum and another metal element.
  • an antiviral agent is likely to inactivate a virus such as adenovirus, and thus can bring a particularly excellent antiviral action against adenovirus.
  • the content of platinum particles in the metal particles is not particularly limited, and for example, the platinum particles can be 10 parts by mass or more and 100 parts by mass or more with respect to 100 parts by mass of the metal particles. Is preferred. In particular, when the metal particles do not include the silver particles described later, the platinum particles can be 70 parts by mass or more based on 100 parts by mass of the metal particles, more preferably 80 parts by mass or more, and 90 parts by mass. It is more preferable that the amount is not less than 99 parts by weight, and particularly preferably not less than 99 parts by mass.
  • the metal particles may be composed only of platinum particles.
  • the average particle size of the platinum particles is not particularly limited and can be 10 to 200 nm.
  • the average particle diameter of the platinum particles referred to in the present specification means a value measured by a zeta potential measuring device (Zetasizer Nano ZS90, manufactured by Malvern).
  • the metal particles may further contain silver particles in addition to platinum particles. Although silver particles alone do not show an antiviral effect, when combined with platinum particles, silver particles can also be an active ingredient in an antiviral agent. When the metal particles include platinum particles and silver particles, the antiviral agent can provide a markedly high antiviral effect against various viruses including adenovirus.
  • the silver particles have silver (Ag) as a constituent component.
  • the silver particles are usually formed of a simple element of silver, but may contain a silver compound such as a silver oxide. In addition, the silver particles may contain an alloy of silver and another metal element.
  • the content ratio of platinum particles and silver particles constituting the metal particles is not particularly limited.
  • the silver particles may be included in an amount of 0.01 to 1000 parts by mass per 100 parts by mass of platinum particles.
  • the lower limit of the content of the silver particles per 100 parts by mass of platinum particles is 0.05 parts by mass, 0.1 parts by mass, 0.2 parts by mass, 0.5 parts by mass, 1 part by mass, and 3 parts by mass. Preferred in order.
  • the upper limit of the content of the silver particles is preferably 700 parts by mass, more preferably 100 parts by mass, further preferably 50 parts by mass, and 30 parts by mass based on 100 parts by mass of the platinum particles. It is particularly preferable that the amount is parts by mass.
  • the antiviral agent is preferably 10 to 99.99 parts by mass, more preferably 30 to 95 parts by mass, and further preferably 30 to 95 parts by mass with respect to 100 parts by mass in total of the platinum particles and the silver particles. It is preferably contained in an amount of 50 to 90 parts by mass.
  • the average particle diameter of silver particles is not particularly limited, and can be 10 to 200 nm.
  • the average particle diameter of the silver particles in the present specification means a value measured by a zeta potential measuring device (Zetasizer Nano ZS90, manufactured by Malvern).
  • the metal particles can be formed of only platinum particles and silver particles, or can contain other metal components as necessary.
  • the total amount of platinum particles and silver particles is preferably 80% by mass or more, more preferably 90% by mass or more, and particularly preferably 95% by mass or more.
  • the metal particles include platinum particles and silver particles
  • the platinum particles and the silver particles can exist independently of each other, or the platinum particles and the silver particles form composite particles due to aggregation or the like. It can also be formed.
  • the platinum particles and the silver particles may coagulate and exist. The presence or absence of formation of composite particles can be confirmed by a transmission electron microscope (TEM).
  • TEM transmission electron microscope
  • the form of the composite particle is not particularly limited.
  • the composite particles may include particles formed by aggregating a large number of platinum particles and silver particles. More specifically, a large number of particles (primary particles) are regularly or irregularly aggregated to form so-called secondary particles, whereby composite particles containing platinum particles and silver particles can be formed. ..
  • the antiviral agent is likely to exert an excellent antiviral effect.
  • the composite particles may be formed, for example, by aggregating particles having similar shapes with each other, or may have a so-called core-shell structure having a structure in which other particles cover the surface of core particles. it can.
  • the core particles may be formed of only one particle or may be an aggregate of a plurality of particles. It is preferable that the composite particles have a core-shell structure because they are easy to produce and can easily exhibit an excellent antiviral effect.
  • the particles forming the core may be either platinum particles or silver particles, and the core particles may include both platinum particles and silver particles.
  • the particles forming the shell (shell particles) may be either platinum particles or silver particles, and the shell particles may include both platinum particles and silver particles.
  • the size of the core particles is usually larger than the size of the shell particles.
  • the core particles can be silver particles and the shell particles can be platinum particles.
  • the reverse is also possible.
  • the average particle size of the composite particles is not particularly limited.
  • the average particle size of the composite particles is preferably 10 to 500 nm from the viewpoint that the composite particles are easily dispersed in an aqueous solvent and that a more excellent antiviral effect is easily exhibited.
  • the lower limit of the average particle size of the composite particles is more preferably 20 nm, and particularly preferably 30 nm.
  • the upper limit of the average particle size of the composite particles is more preferably 300 nm, and particularly preferably 200 nm.
  • the average particle size of the composite particles in the present specification refers to a value measured by a zeta potential measuring device (Zetasizer Nano ZS90, manufactured by Malvern).
  • the average particle size of platinum particles and silver particles forming the composite particles is not particularly limited.
  • the platinum particles can have an average particle diameter of 10 to 200 nm
  • the silver particles can have an average particle diameter of 20 to 480 nm.
  • the average particle size of the platinum particles and the silver particles forming the composite particles referred to in the present specification is determined by energy dispersive X-ray spectroscopy (EDS) after the composition of each particle shown in the TEM image is specified.
  • EDS energy dispersive X-ray spectroscopy
  • 50 particles are randomly selected by direct observation with a transmission electron microscope (TEM), and the equivalent circle diameters of these particles are measured and arithmetically averaged.
  • the shape (planar shape) of the composite particles is not particularly limited, and examples thereof include spherical particles, elliptic spherical particles, amorphous particles, polygonal particles, fibrous particles, needle-like particles, flake-like particles, and porous particles. It
  • the shapes of platinum particles and silver particles contained in the composite particles are not particularly limited.
  • Examples of the platinum particles and silver particles include spherical particles, elliptic spherical particles, irregular particles, polygonal particles, fibrous particles, needle particles, flake particles, and porous particles. Even when the platinum particles and the silver particles do not form a composite particle size, the shapes of the platinum particles and the silver particles can be the same as above.
  • -Composite particles can be formed only of platinum particles and silver particles, and can also contain components such as other metals as necessary.
  • the total amount of platinum particles and silver particles in the total mass of the composite particles is preferably 80% by mass or more, more preferably 90% by mass or more, and particularly preferably 95% by mass or more.
  • the antiviral agent may include an aqueous solvent in addition to the metal particles.
  • the metal particles in the antiviral agent, can be present dispersed in an aqueous solvent. The same applies when the metal particles form composite particles containing platinum particles and silver particles.
  • the aqueous solvent is not particularly limited, and examples thereof include water, a lower alcohol having 1 to 3 carbon atoms, etc., or a mixed solvent thereof.
  • water various kinds of water such as distilled water, tap water, industrial water, ion-exchanged water, deionized water, pure water, and electrolyzed water can be used.
  • the aqueous solvent can contain 90% by mass or more of water, and 99% by mass or more of water. Is particularly preferable.
  • the content of the metal particles in the aqueous solvent is not particularly limited and can be arbitrarily adjusted within a range in which desired antiviral performance is exhibited.
  • the total amount of the metal particles can be 0.01 to 1000 mass ppm with respect to the total mass of the aqueous solvent. In this case, the antiviral agent is likely to exert an excellent antiviral effect.
  • the total amount of the metal particles is more preferably 0.1 to 500 mass ppm with respect to the total mass of the aqueous solvent.
  • the antiviral effect is not sufficiently exerted when the concentration becomes low, but in the antiviral agent of the present invention, the active ingredient, that is, the concentration of the metal particles is lower than in the conventional case. Both have the advantage that the antiviral effect is unlikely to decrease. Therefore, by using a dispersion liquid in which the metal particles are dispersed in an aqueous solvent as an antiviral agent, it is possible to exhibit an unprecedented excellent antiviral effect.
  • the pH of the antiviral agent is not particularly limited. From the viewpoint that the dispersion stability of platinum particles and silver particles tends to be good, the pH of the antiviral agent is preferably 3 to 7, more preferably 3.5 to 6, and 3.5 to 4. 5 is particularly preferable.
  • the dosage form of the antiviral agent is not particularly limited, and can be appropriately selected according to its application.
  • the dosage form for example, when it contains the above-mentioned aqueous solvent, it is a liquid agent such as an emulsion, a suspension agent, a dispersant, an aerosol agent, etc. It is also possible to use a solid agent or a semi-solid agent.
  • the antiviral agent may contain other components in addition to the aqueous solvent or in place of the aqueous solvent.
  • various additives can be mentioned as long as the effects of the present invention are not impaired.
  • additives examples include other antiviral agents other than the antiviral agent of the present invention, microbial control agents (specifically, antibacterial agents, bactericides, preservatives, algae agents, antifungal agents, etc.), pH adjusters, antioxidants, solvents, binders, carriers, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, humectants, colorants, fragrances.
  • microbial control agents specifically, antibacterial agents, bactericides, preservatives, algae agents, antifungal agents, etc.
  • pH adjusters specifically, antioxidants, solvents, binders, carriers, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, humectants, colorants, fragrances.
  • antiviral agents such as a chelating agent, a light stabilizer, and an antif
  • examples of the pH adjuster include acids such as hydrochloric acid, nitric acid, sulfuric acid, lactic acid, acetic acid, and citric acid, and alkali metal salts, alkaline earth metal salts, and ammonium salts of these acids.
  • the pH adjustor may be a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, triethylamine, trimethylamine, or ammonia. These pH adjusters can be used alone or in combination of two or more as needed.
  • the content of the additive is 5% by mass or less, preferably 1% by mass or less, more preferably 0.1% by mass or less with respect to the total mass of the platinum particles, the silver particles and the aqueous solvent.
  • the amount can be less than or equal to mass%, particularly preferably less than or equal to 0.05% by mass.
  • the virus that can be inactivated by an antiviral agent is not particularly limited.
  • the antiviral agent can target, for example, known enveloped viruses (viruses having an envelope) and non-enveloped viruses (viruses not having an envelope) as target viruses.
  • influenza virus eg, A type, B type, etc.
  • rubella virus e.g., Ebola virus, coronavirus, measles virus, varicella-zoster virus, herpes virus, mumps virus, arbovirus, RS virus, SARS.
  • Virus hepatitis virus (eg, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, etc.), yellow fever virus, AIDS virus, rabies virus, hantavirus, dengue virus, nipah virus , Lyssa virus and the like.
  • non-enveloped viruses examples include adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, polyomavirus, BK virus, rhinovirus and the like.
  • anti-herpes virus for example, herpes simplex virus
  • influenza virus for example, A type, B type, etc., preferably A type
  • herpes virus for example, herpes simplex virus
  • Viral agents can exert excellent antiviral effects.
  • the antiviral agent can exert an excellent antiviral action, especially against adenovirus. Even when the target virus contains one or more selected from the group consisting of herpes simplex virus and adenovirus, the antiviral effect of the antiviral agent is effectively exerted.
  • the antiviral agent can exert a particularly excellent antiviral activity against one or more selected from the group consisting of herpes simplex virus, adenovirus and influenza virus, and the antiviral agent contains silver particles. Even if it does not exist, the effect can be exhibited.
  • the antiviral agent when the target virus is adenovirus, the antiviral agent can exert an excellent antiviral effect without containing silver particles. Therefore, the antiviral agent containing platinum particles or the antiviral agent containing platinum particles but not silver particles can be particularly preferably used for adenovirus.
  • the metal particles include silver particles in addition to platinum particles, it can bring outstanding antiviral action against adenovirus, and also against viruses such as herpes virus, only platinum particles can be obtained. It has a remarkably superior antiviral effect as compared with the case of using an antiviral agent containing Therefore, an antiviral agent containing both platinum particles and silver particles can be particularly preferably used for viruses such as adenovirus and herpes virus.
  • the antiviral agent can be widely used in various fields requiring antiviral properties, and can be used in various fields such as medical care, industry, cleaning, food and household use.
  • the antiviral agent can be used in various articles used in each of these fields.
  • the virus can be inactivated, and for example, the virus can have a growth inhibitory effect, a killing effect and an infection spread preventing effect.
  • Targets to be treated or treated with antiviral agents include skin surfaces such as fingers, medical devices, industrial products used in various fields, and raw materials thereof.
  • the medical device is not particularly limited, and various medical devices used in various medical settings can be exemplified.
  • medical devices for ophthalmology medical devices for dental treatment, medical devices for internal medicine, surgical instruments
  • various medical instruments used in hospital rooms and the like can be widely cited.
  • ophthalmic medical instruments include a scissor, a scissor, an eyelid opener, a needle holder, a cannula handpiece, a spatula, a cataract surgery instrument, a retina/vitreous surgery instrument, a glaucoma surgery instrument, and a corneal surgery instrument.
  • ophthalmic medical instruments include a scissor, a scissor, an eyelid opener, a needle holder, a cannula handpiece, a spatula, a cataract surgery instrument, a retina/vitreous surgery instrument, a glaucoma surgery instrument, and a corneal surgery instrument.
  • examples thereof include instruments, instruments for external ocular surgery, surgical knives, cannulas, needles, and the like.
  • Other articles treated with antiviral agents include clothes such as white coats, masks, glasses, gloves, doorknobs, walls and floors of stairs such as indoors and corridors, handrails such as stairs and elevators, toilet walls, and toilet bowls. And toilet seats, bath tubs and floors, kitchen chopping boards and knives, gas stoves, tableware, ticket vending machine panels, hangers, computer mice and keyboards, mobile phones and smartphones, writing instruments, air purifiers and air conditioner filters. , Filters for water purifiers, filters and nozzles for vacuum cleaners, mops, carpets, curtains, windows and the like.
  • the antiviral agent for medical equipment, especially for ophthalmic medical equipment (that is, for ophthalmic medical equipment). It is known that 90% or more of viral conjunctivitis can be caused by adenovirus, and as described above, the antiviral agent of the present invention can bring an excellent antiviral action against adenovirus. is there.
  • Examples of the usage mode in which the article is treated with the antiviral agent include a mode in which the antiviral agent is attached to the surface of the article for use. This allows the article to be treated with an antiviral agent to inactivate the virus already attached to the article, or to inactivate the virus attached to the article treated with the antiviral agent. it can. Furthermore, it is possible to inactivate viruses already attached to other articles with which the article is to come into contact.
  • the method of attaching the antiviral agent to the article surface can be appropriately selected according to the type of article.
  • the antiviral agent can be attached to the article by a method of spraying the article with the antiviral agent, a method of applying the antiviral agent to the article, a method of dipping or contacting the article with the antiviral agent, and the like. After treating the article with an antiviral agent, volatile components such as aqueous solvents may volatilize.
  • the antiviral agent of the present invention can be used as a disinfecting solution in various fields such as medical, industrial, cleaning, food and household use, or can be combined with other agents to prepare a disinfecting solution.
  • the method for producing the antiviral agent is not particularly limited.
  • platinum particles and optionally added silver particles may be produced by a known method to obtain an aqueous dispersion of metal particles, and an antiviral agent may be produced using this aqueous dispersion of metal particles. it can.
  • the metal particles include platinum particles and silver particles
  • the antiviral agent can be obtained by producing and mixing dispersions of the both.
  • the aqueous dispersion of platinum particles and the aqueous dispersion of silver particles can be obtained, for example, by a known production method, or can be obtained from a commercially available product.
  • the antiviral agent can also be produced by a method of mixing a precursor of platinum particles and a precursor of silver particles (hereinafter, referred to as "production method A"). ..
  • the platinum particle precursor is, for example, a compound containing platinum and means a compound capable of forming platinum particles by chemical treatment.
  • the precursor of silver particles is, for example, a compound containing silver, and means a compound capable of forming silver particles by chemical treatment.
  • platinum particle precursor for example, a platinum complex can be mentioned.
  • the platinum complex can be obtained, for example, by complexing a platinum source.
  • the platinum source include platinum oxides, hydroxides, chlorides, carbonates, acetates, nitrates, oxalates, phosphates, chloride complexes and the like.
  • the platinum source complexing treatment can be carried out, for example, by using various organic salts and reacting the organic salts with the platinum source. Above all, it is preferable to use trisodium citrate as the organic salt. Trisodium citrate may be a hydrate. Complexation of the platinum source can be carried out, for example, in water.
  • the ratio of platinum source and organic salt used in complexing the platinum source is not particularly limited.
  • the platinum source can be complexed with 1 to 5 mol of an organic salt based on 1 mol of platinum contained in the platinum source.
  • a silver complex As a precursor of silver particles, for example, a silver complex can be mentioned.
  • the silver complex can be obtained, for example, by complexing a silver source.
  • the silver source include silver oxide, hydroxide, chloride, carbonate, acetate, nitrate, oxalate, and phosphate.
  • the complexing treatment of the silver source can be performed, for example, by using various organic salts and reacting the organic salts with the silver source. Above all, it is preferable to use trisodium citrate as the organic salt. Trisodium citrate may be a hydrate.
  • Complexation of the silver source can be performed in water, for example.
  • the ratio of the silver source and the organic salt used for complexing the silver source is not particularly limited.
  • the silver source can be complexed with 1 to 5 mol of organic salt based on 1 mol of platinum contained in the silver source.
  • the method of mixing the platinum particle precursor and the silver particle precursor is not particularly limited.
  • a method of mixing a solution (for example, an aqueous solution) of the precursor of platinum particles with the aqueous solvent and a solution (for example, an aqueous solution) of the precursor of the silver particles with the aqueous solvent When the solutions are mixed with each other, for example, a dropping method in which one solution is dropped into the other solution can be adopted. In the case of this dropping method, for example, aggregated particles having the above-mentioned core-shell structure are likely to be formed.
  • the dropping method is not particularly limited, and for example, a commercially available dropping device, a dropping pump, or the like can be used.
  • the temperature at the time of mixing is not particularly limited, and may be, for example, room temperature, specifically 15 to 35° C.
  • the mixing ratio of both is not particularly limited, either, so that the platinum particles and the silver particles in the antiviral agent have a desired content ratio.
  • the amount of the precursor used and the amount of the silver particle precursor used can be appropriately adjusted.
  • the platinum particle precursor and the silver particle precursor may be mixed to obtain a mixed solution, and then an acid may be added to the mixed solution.
  • an acid By adding this acid, the pH of the mixed solution is appropriately adjusted, whereby generation of particles is promoted, and a dispersion containing platinum particles and silver particles can be easily and quickly obtained.
  • Examples of the acid added to the mixed solution include inorganic acids such as hydrochloric acid, nitric acid and sulfuric acid; organic acids such as acetic acid, citric acid and succinic acid. Among these, it is preferable to use an organic acid, and it is particularly preferable to use citric acid, from the viewpoint that the dispersion stability of the produced composite particles is good.
  • the dispersion containing the produced platinum particles and silver particles also has excellent dispersion stability.
  • the method of adding the acid is not particularly limited, and for example, the acid can be made into an aqueous solution and added to the mixed solution.
  • an aqueous solvent can be mixed if necessary to adjust the concentration of the antiviral agent to a desired range. Accordingly, the above-mentioned additives can be added to obtain an antiviral agent.
  • the entire amount of the aqueous solution containing the platinum complex was added dropwise to the aqueous solution containing the silver complex with stirring over 60 minutes, and after the completion of the dropping, the stirring was continued for further 60 minutes to obtain a mixed solution.
  • About 0.6 mL of 50% aqueous citric acid solution was added dropwise to the obtained mixed solution to adjust the pH of the mixed solution to 4, and the mixture was further stirred for 60 minutes to obtain an aqueous dispersion containing platinum particles and silver particles.
  • the average particle size of the metal particles in the obtained dispersion was measured with a zeta potential measuring device (Zetasizer Nano ZS90, manufactured by Malvern Co.), and was 100 nm, and the mass ratio of platinum particles and silver particles was 6:4. there were.
  • the content of metal particles in water in the aqueous dispersion was 166 mass ppm as confirmed by ICP-MS (ElanDRCII manufactured by Perkin Elmer Co.), of which platinum was 100 mass ppm and silver was 66 mass ppm. there were.
  • ICP-MS ElanDRCII manufactured by Perkin Elmer Co.
  • the composite particles were particles having a core-shell structure.
  • Component analysis of each particle shown in the TEM image was performed by energy dispersive X-ray spectroscopy (EDS), and it was also found that in the core-shell structure, the core was formed of silver particles and the shell was formed of platinum particles. ..
  • TEM/EDS HITACHI H-7100, acceleration voltage 100 kV was used.
  • Example 1 An aqueous dispersion containing platinum particles and silver particles obtained in Synthesis Example 1-1 was prepared.
  • the sample solutions at the respective dilution ratios which were diluted 4 times, 16 times, 64 times and 256 times by adding the sodium citrate aqueous solution prepared in Synthesis Example 3-1, as required. Prepared.
  • Example 2 An aqueous dispersion containing platinum particles and silver particles obtained in Synthesis Example 1-2 was prepared.
  • the sample solutions at the respective dilution ratios which were diluted 4 times, 16 times, 64 times and 256 times by adding the sodium citrate aqueous solution prepared in Synthesis Example 3-1, as required. Prepared.
  • Example 3 An aqueous dispersion containing the platinum particles obtained in Synthesis Example 2-1 was prepared.
  • the sample solutions at the respective dilution ratios which were diluted 4 times, 16 times, 64 times and 256 times by adding the sodium citrate aqueous solution prepared in Synthesis Example 3-1, as required. Prepared.
  • ⁇ Evaluation method> Antiviral test against herpes simplex virus
  • An antiviral test against herpes simplex virus was carried out as follows using the sample solutions obtained in the respective Examples and Comparative Examples. In this test, herpes simplex virus type 1 VR-3 strain was used. The virus solution (4.4 ⁇ 10 7 pfu/mL) was stored at ⁇ 80° C. and thawed and used in the assay.
  • a reaction solution was prepared by mixing 10 ⁇ L of the virus solution and 190 ⁇ L of the sample solution, allowed to stand at room temperature for a predetermined period of time, and then Dulbecco's modified Eagle MEM medium (MEM-CS2; Nissui) supplemented with 2% of newborn calf serum. The reaction was stopped by diluting with (Pharmaceutical). The virus titer in this reaction solution was measured by a plaque assay using Vero cells (African green monkey kidney cells, RIKEN Cell Bank) precultured in a 24-well culture plate. Specifically, 0.2 mL of each diluted solution of the reaction solution was added to the cells, and the virus was adsorbed to the cells in a CO 2 incubator at 37° C.
  • Vero cells African green monkey kidney cells, RIKEN Cell Bank
  • the virus solution was removed, and MEM-CS2 containing 0.5% methyl cellulose was overlaid.
  • the plate was incubated in an incubator at 37° C. in 5% CO 2 and 100% humidity for 5 days. After culturing, the cells were fixed with 10% formalin solution, stained with 0.25% crystal violet staining solution, and the number of plaques was visually measured.
  • Antiviral test against adenovirus Using the sample solutions obtained in the respective examples and comparative examples, an antiviral test against adenovirus was conducted as follows. In this test, serotype 5 adenovirus was used. The virus solution (2.6 ⁇ 10 8 TCID 50 /mL) was stored at ⁇ 80° C. and thawed and used in the assay.
  • a reaction solution was prepared by mixing 10 ⁇ L of the virus solution and 190 ⁇ L of the sample solution, allowed to stand at room temperature for a predetermined time, and then 10% fetal bovine serum was added to Dulbecco's modified Eagle MEM medium (MEM-FCS10; Nissui). The reaction was stopped by diluting with (Pharmaceutical).
  • MEM-FCS10 Dulbecco's modified Eagle MEM medium
  • the reaction was stopped by diluting with (Pharmaceutical).
  • the virus titer in this reaction solution the cytopathic effect after infection of A549 cells (human tracheal epithelial cells, RIKEN Cell Bank) precultured in a 96-well culture plate was used as a TCID 50 value (50% tissue culture infectious titer). I asked.
  • the cells were cultured in an incubator at 37° C. in 5% CO 2 and 100% humidity for 7 days. After culturing, the cells were fixed with 10% formalin solution and stained with 0.25% crystal violet staining solution. It was observed whether or not the cytopathic effect due to virus infection appeared in each well, and the virus concentration (TCID 50 value) in which virus infection occurred in 50% of the wells was calculated by the Behrens-Karber method.
  • influenza test against influenza A virus was conducted as follows. In this test, influenza A virus A/Aichi/2/68 (H3N2) strain was used. The virus solution (2.8 ⁇ 10 4 pfu/mL) was stored at ⁇ 80° C. and thawed and used in the assay.
  • a reaction solution was prepared by combining 10 ⁇ L of the virus solution and 190 ⁇ L of the sample solution, allowed to stand at room temperature for a predetermined period of time, and then Dulbecco's modified Eagle MEM medium (MEM-FCS10; Nissui) containing 10% fetal bovine serum. The reaction was stopped by diluting with (Pharmaceutical). The virus titer in this reaction solution was measured by a plaque assay using MDCK cells (canine tubular epithelial cells, distributed from Sendai Medical Center/Virus Center) precultured in a 12-well culture plate.
  • MDCK cells canine tubular epithelial cells, distributed from Sendai Medical Center/Virus Center
  • each diluted solution of the reaction solution was added to the cells, and the virus was adsorbed to the cells in a CO 2 incubator at 37° C. for 1 hour. After adsorption, the virus solution was removed, and Dulbecco's modified Eagle MEM medium containing 1% agarose heated and dissolved, 10% bovine albumin, and 5 ⁇ g/mL trypsin was overlaid. The plate was allowed to stand at room temperature for about 10 minutes to solidify the agar, and then cultured for 2 days in an incubator at 37°C in 5% CO 2 and 100% humidity. After culturing, the cells were fixed with 10% formalin solution, stained with 0.25% crystal violet staining solution, and the number of plaques was visually measured.
  • Example 1 Reaction time for Example 1 (platinum particles and silver particles), Example 3 (platinum particles), Comparative Example 1 (pure water), Comparative Example 2 (blank; sodium citrate aqueous solution) and Comparative Example 3 (silver particles) was confirmed and the virus inactivating effect was confirmed.
  • Table 1 and Table 2 show Example 1 (platinum particles and silver particles), Example 3 (platinum particles), Comparative Example 1 (pure water), Comparative Example 2 (blank; sodium citrate aqueous solution) and Comparative Example, respectively.
  • 3 shows the results of antiviral test against herpes simplex virus (Table 1), adenovirus (Table 2) and influenza virus (Table 3) in 3 (silver particles).
  • Example 3 and Example 1 showed an inactivating effect on herpes simplex virus, adenovirus and influenza virus by exposure for 1 minute.
  • Comparative Example 3 did not show an inactivating effect against herpes simplex virus even after 30 minutes of exposure, and did not show an inactivating effect against adenovirus even after 1 hour of exposure.
  • influenza virus was inactivated to about 1% with the blank sodium citrate solution (Comparative Example 2), and a slight enhancement of inactivation was observed in Comparative Example 3.
  • Example 2 Next, targeting herpes simplex virus and adenovirus that are not inactivated at all by the blank solution, the reaction time was set to 10 minutes for Example 3 and Example 1, and the stock solutions (water dispersion) prepared in Example 3 and Example 1 were used. The solution) was diluted with an aqueous solution of sodium citrate (Comparative Example 2) to examine the virus inactivating effect at a lower concentration.
  • the antiviral test method is the same as in Experiment 1.
  • Table 4 and Table 4 show the virus titer when Comparative Example 1 (pure water) was used instead of the sample solution as a control (100%), and as a percentage (average of three or more assays) relative to the control. It is 5.
  • Table 4 shows the results of antiviral test against herpes simplex virus
  • Table 5 shows the results of antiviral test against adenovirus.
  • Example 1 since the content of platinum particles in each sample solution of Example 1 is smaller than the content of platinum particles in the sample solution of Example 3 having the same dilution ratio, as described above, the silver particles are antiviral. Considering that it showed no effect, Example 1 was expected to show a lower antiviral effect than Example 3 (for example, considering the platinum content ratios of Example 1 and Example 3, It was thought that there would be a difference of about 1.5 times). However, it was found that the addition of silver, which does not show an antiviral effect, improves the antiviral effect by several times or more in all cases.
  • the present inventors have found that the antiviral effect is improved several times or more (synergistic effect) by combining platinum particles expressing antiviral property and silver particles not exhibiting antiviral property. Can be said to be the first to be found.
  • Example 3 Next, for Example 1 (dispersion liquid containing 100 mass ppm of platinum and 66 mass ppm of silver) and Example 2 (dispersion liquid containing 100 mass ppm of platinum and 20 mass ppm of silver), the reaction time was 10 minutes and the virus was used. The inactivating effect was examined. The dilution ratio was 16 times for herpes simplex virus and 256 times for adenovirus. The antiviral test method is the same as in Experiment 1.
  • Table 6 shows the inactivating effect on herpes simplex virus as a virus titer and a percentage of the control
  • Table 7 shows the inactivating effect on adenovirus as a virus titer and a percentage of the control (as a control). Comparative Example 1 is also listed in the table).
  • Example 1 and Example 2 had a good inactivating effect on both herpes simplex virus and adenovirus.
  • the antiviral agent containing platinum particles and the antiviral agent containing platinum particles and silver particles can rapidly inactivate viruses such as herpes simplex virus, adenovirus and influenza virus. .. It was found that the dispersion liquids containing the platinum particles and the silver particles of Example 1 and Example 2 can exert the antiviral effect even when the concentration is low (the concentration of the active ingredient is low). Further, it was found that the antiviral agent containing the platinum particles of Example 3 can exert an excellent antiviral effect against adenovirus without containing silver particles.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent antivirus capable d'inactiver rapidement divers types de virus et un procédé destiné à l'inactivation des virus. L'agent antivirus selon la présente invention contient des particules métalliques. Les particules métalliques comprennent des particules de platine. De plus, l'agent antivirus contient de préférence des particules de platine et des particules d'argent. L'agent antivirus selon la présente invention contient de préférence les particules de platine suivant une quantité de 10 à 99,99 parties en masse par rapport à 100 parties en masse du total des particules de platine et des particules d'argent. L'agent antivirus selon la présente invention peut inactiver rapidement divers types de virus.
PCT/JP2020/004291 2019-02-06 2020-02-05 Agent antivirus et procédé destiné à l'élimination de virus Ceased WO2020162485A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202080012642.7A CN113395901A (zh) 2019-02-06 2020-02-05 抗病毒剂以及病毒的去除方法
JP2020542332A JP6820579B2 (ja) 2019-02-06 2020-02-05 抗ウイルス剤及びウイルスの除去方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-020116 2019-02-06
JP2019020116 2019-02-06

Publications (1)

Publication Number Publication Date
WO2020162485A1 true WO2020162485A1 (fr) 2020-08-13

Family

ID=71947967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/004291 Ceased WO2020162485A1 (fr) 2019-02-06 2020-02-05 Agent antivirus et procédé destiné à l'élimination de virus

Country Status (3)

Country Link
JP (2) JP6820579B2 (fr)
CN (1) CN113395901A (fr)
WO (1) WO2020162485A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261467A1 (fr) * 2020-06-23 2021-12-30 佐々木化学工業株式会社 Composition contenant de l'hydrogénocitrate de diargent, son procédé de production, agent antibactérien ou agent antiviral l'utilisant, et son procédé de production
JP2022164635A (ja) * 2021-04-16 2022-10-27 佐々木化学工業株式会社 クエン酸水素二銀含有組成物及びその製造方法、並びにこれを用いた抗菌剤又は抗ウイルス剤及びその製造方法
JPWO2023234239A1 (fr) * 2022-05-30 2023-12-07
WO2023234242A1 (fr) 2022-05-30 2023-12-07 信越化学工業株式会社 Composition antivirale et élément ayant ladite composition sur sa surface

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272307A (ja) * 2004-03-23 2005-10-06 Dd Planning Kk 抗菌・防カビ・消臭剤の噴霧方法及びその噴霧装置
JP2013241368A (ja) * 2012-05-21 2013-12-05 Bio Epoch Kk 白金水溶液及び水溶性切削液浄化装置
JP2014098546A (ja) * 2010-12-24 2014-05-29 Bioface Co Ltd Tokyo Research Laboratory プラチナシールド技術、プラチナ触媒化学技術、プラチナ固定技術のいずれかを用いた家電製品、及び加湿器
JP2018035427A (ja) * 2016-09-02 2018-03-08 株式会社サンテック 白金ナノコロイドの製造方法と粒度分布幅の狭く安定性の高いシングルナノ白金コロイド水溶液
JP2018135347A (ja) * 2015-11-09 2018-08-30 大阪ガスケミカル株式会社 微生物防除剤及び殺ダニ組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1552205A (zh) 2003-05-30 2004-12-08 中国科学院大连化学物理研究所 具有吸附和杀灭病毒活性的纳米催化剂
DE102008039072A1 (de) * 2008-08-21 2010-02-25 Bayer Materialscience Ag Elektrodenmaterial, Elektrode und ein Verfahren zur Chlorwasserstoffelektrolyse
US20120294923A1 (en) 2009-12-01 2012-11-22 Sumitomo Chemical Company, Limited Antiviral agent and antiviral agent functional product using the same
CN107180665A (zh) * 2016-03-11 2017-09-19 上海卡翱投资管理合伙企业（有限合伙） 应用于低温共烧陶瓷的灌孔过渡金铂银孔浆及其制备方法
WO2017170878A1 (fr) * 2016-03-30 2017-10-05 大阪ガスケミカル株式会社 Élément d'apiculture et son procédé de production
TWI702051B (zh) * 2019-01-09 2020-08-21 張文禮 高效奈米淡斑、亮白、保濕活化劑及其製法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005272307A (ja) * 2004-03-23 2005-10-06 Dd Planning Kk 抗菌・防カビ・消臭剤の噴霧方法及びその噴霧装置
JP2014098546A (ja) * 2010-12-24 2014-05-29 Bioface Co Ltd Tokyo Research Laboratory プラチナシールド技術、プラチナ触媒化学技術、プラチナ固定技術のいずれかを用いた家電製品、及び加湿器
JP2013241368A (ja) * 2012-05-21 2013-12-05 Bio Epoch Kk 白金水溶液及び水溶性切削液浄化装置
JP2018135347A (ja) * 2015-11-09 2018-08-30 大阪ガスケミカル株式会社 微生物防除剤及び殺ダニ組成物
JP2018035427A (ja) * 2016-09-02 2018-03-08 株式会社サンテック 白金ナノコロイドの製造方法と粒度分布幅の狭く安定性の高いシングルナノ白金コロイド水溶液

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021261467A1 (fr) * 2020-06-23 2021-12-30 佐々木化学工業株式会社 Composition contenant de l'hydrogénocitrate de diargent, son procédé de production, agent antibactérien ou agent antiviral l'utilisant, et son procédé de production
US12604898B2 (en) 2020-06-23 2026-04-21 Sasaki Chemical Industry Co., Ltd. Disilver hydrogen citrate-containing composition, method for producing same, antibacterial agent or antiviral agent using same, and method for producing same
JP2022164635A (ja) * 2021-04-16 2022-10-27 佐々木化学工業株式会社 クエン酸水素二銀含有組成物及びその製造方法、並びにこれを用いた抗菌剤又は抗ウイルス剤及びその製造方法
JP7710732B2 (ja) 2021-04-16 2025-07-22 佐々木化学工業株式会社 クエン酸水素二銀含有組成物及びその製造方法、並びにこれを用いた抗菌剤又は抗ウイルス剤及びその製造方法
JPWO2023234239A1 (fr) * 2022-05-30 2023-12-07
WO2023234239A1 (fr) 2022-05-30 2023-12-07 信越化学工業株式会社 Composition antivirale et élément la comprenant sur sa surface
WO2023234242A1 (fr) 2022-05-30 2023-12-07 信越化学工業株式会社 Composition antivirale et élément ayant ladite composition sur sa surface
KR20250016271A (ko) 2022-05-30 2025-02-03 신에쓰 가가꾸 고교 가부시끼가이샤 항바이러스성 조성물 및 해당 조성물을 표면에 갖는 부재
KR20250016272A (ko) 2022-05-30 2025-02-03 신에쓰 가가꾸 고교 가부시끼가이샤 항바이러스성 조성물 및 해당 조성물을 표면에 갖는 부재

Also Published As

Publication number Publication date
CN113395901A (zh) 2021-09-14
JPWO2020162485A1 (ja) 2021-02-18
JP2021050234A (ja) 2021-04-01
JP7509370B2 (ja) 2024-07-02
JP6820579B2 (ja) 2021-01-27

Similar Documents

Publication Publication Date Title
JP7509370B2 (ja) 抗ウイルス剤及びウイルスの除去方法
US4828912A (en) Virucidal product having virucidal and/or germicidal properties
US4897304A (en) Virucidal composition, the method of use and the product therefor
KR870002047B1 (ko) 비루스 박멸용 조성물 및 제품
TWI407906B (zh) 消毒劑
BR112021002911A2 (pt) composições antipatogênicas e métodos das mesmas
EP3012225A1 (fr) Nanomatériau en dioxyde de titane nanoparticulaire modifié avec des groupes fonctionnels et des extraits citriques adsorbés en surface pour l'élimination d'un grand spectre de micro-organismes
CN110917196B (zh) 一种氯喹抑菌消毒液及其应用
WO2013012007A1 (fr) Composition d'agent anti-virus
JP7794814B2 (ja) グラフェン－銀ナノコンポジット及び抗微生物組成物としてのその使用
JP5361533B2 (ja) 環境物質処理剤
Pereira et al. Inactivation of SARS-CoV-2 by a chitosan/α-Ag2WO4 composite generated by femtosecond laser irradiation
JP5837346B2 (ja) ウイルス不活化組成物
JP5189291B2 (ja) 塩化セチルピリジニウムの殺ウイルス活性
JP2017105723A (ja) カリシウイルス不活化効果を有する組成物
US12604898B2 (en) Disilver hydrogen citrate-containing composition, method for producing same, antibacterial agent or antiviral agent using same, and method for producing same
JP3187328U (ja) 抗菌・抗ウイルス性病院用寝具及び衣類
JP5377098B2 (ja) ノロウイルス不活性化剤
JP2015078132A (ja) 抗ウイルス性組成物
CN110876684A (zh) 一种免洗聚六亚甲基胍盐酸盐消毒剂的制备方法
WO2021256540A1 (fr) Préparation d'inactivation virale
JP2006188499A (ja) 除ウイルス剤又は除真菌剤
JP2023079139A (ja) 抗ウイルス剤
JP2022167716A (ja) 抗菌及び抗ウイルス剤
Zinn et al. Rapidly self-sterilizing PPE capable of destroying 100% of microbes in 30-60 seconds

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020542332

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20752109

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20752109

Country of ref document: EP

Kind code of ref document: A1